Exebacase

Summary

Exebacase (CHEMBL4297925) is a phase-3 clinical-stage enzyme; indicated across 2 conditions including bacterial endocarditis and staphylococcal infection.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Enzyme
• Indications: 2 conditions
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297925
Name	Exebacase
Type	Enzyme
Max phase	3

Also known as: Cf-301, CF-301, CF301, Exebacasa, Exebacase, EXEBACASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
bacterial endocarditis	1	MONDO:0006669	EFO:1000830
staphylococcal infection	1	MONDO:0024313	EFO:1001849

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04160468	PHASE3	TERMINATED	Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
NCT03163446	PHASE2	COMPLETED	Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia
NCT02439359	PHASE1	COMPLETED	A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects
NCT04597242	Not specified	NO_LONGER_AVAILABLE	Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).